Translation of Novel Therapeutic Targets in Multiple Myeloma
多发性骨髓瘤新治疗靶点的转化
基本信息
- 批准号:8788808
- 负责人:
- 金额:$ 43.19万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2013
- 资助国家:美国
- 起止时间:2013-01-22 至 2015-12-31
- 项目状态:已结题
- 来源:
- 关键词:AttentionBortezomibBrainCancer Therapy Evaluation ProgramCell LineCellsCharacteristicsChemical StructureChemicalsChronicClinicClinicalClinical TrialsCombined Modality TherapyCyclin-Dependent Kinase 5DevelopmentDiseaseDrug FormulationsExhibitsFosteringG-Protein-Coupled ReceptorsGRK6 geneGenomicsGoalsHealthIn VitroInhibitory Concentration 50Knockout MiceLeadLibrariesMalignant NeoplasmsMediator of activation proteinModelingMolecularMolecular ProbesMultiple MyelomaPatientsPharmaceutical PreparationsPhasePhase II Clinical TrialsPhosphotransferasesProcessProteasome InhibitionProteasome InhibitorRNA InterferenceRefractoryRegimenRelapseResearchResistanceSamplingSeriesSpecificityStagingStructure-Activity RelationshipTFE3 geneTNK1 geneTOP1 geneTherapeutic IndexTissuesToxic effectTransgenic OrganismsTranslationsValidationWorkbaseclinical efficacycytotoxicitygenome-wideimprovedin vivoinhibitor/antagonistinnovationinterestkinase inhibitorlenalidomidenew therapeutic targetnovelpreclinical studyresearch clinical testingscaffoldscreeningsmall moleculesmall molecule librariestumor
项目摘要
DESCRIPTION (provided by applicant): This application will build on genome wide RNA interference (RNAi) screens which successfully identified unique druggable targets in Myeloma. These targets were pursued into the clinic and remarkably have confirmed a new and active kinase inhibitor previously unrecognized as critical to Myeloma survival; cyclin dependent kinase 5 (CDK5). The screen also identified novel opportunities to target a second new, and hematologic tissue restricted, kinase target: G protein coupled receptor 6 (GRK6). We therefore present an ambitious short and midterm plan to further clinically develop and understand the molecular basis for the activity of the CDK5 inhibitor, SCH727965, while taking a longer term view by pursuing novel chemical entities targeting GRK6. The aims of the proposal are to: 1) Further advance CDK5 suppressive therapy in the clinic by conducting a Phase Ib/II clinical trial of SCH727965 in combination with the proteasome inhibitor Carfilzomib in advanced Myeloma, 2) As part of this clinical trial we will examine in vivo mediators of sensitivity and resistance t the combination therapy, 3) Using molecular probe chemicals generated from a 120,000 compound, scaffold enriched, library screen we will examine a panel of 40 novel GRK6 specific inhibitors for target specificity, potency, in vivo activity and toxicity against Myeloma. Lead compounds will be assessed for toxicity profile as a prelude to lead optimization and early clinical development, 4) we will continue analysis of targets identified in BTZ sensitizing screens
that have not yet been fully validated. We have focused early attention on GRK6 and CDK5 as the strongest hits with the highest apparent therapeutic index but other novel and interesting proteasome inhibitor sensitizing targets identified in our RNA interference screens require further validation and analysis and include the sensitizers BAZ1B, CDC42SE2, MDM4, NME7, RAB8B, TFE3, TNFAIP3, TNK1, TOP1, VAMP2, and YY1. The proposed work is therefore highly innovative, pursuing at least two new and novel targets to clinical conclusion and is of high significance as further breakthroughs in therapy and new therapeutic targets for Myeloma are needed to turn the disease from controllable to curable.
描述(由申请人提供):本申请将建立在全基因组RNA干扰(RNAi)筛选的基础上,该筛选成功鉴定了骨髓瘤中独特的可药用靶点。这些目标被追求到临床上,并显着证实了一种新的和活性激酶抑制剂,以前未被识别为骨髓瘤生存的关键;细胞周期蛋白依赖性激酶5(CDK 5)。筛选还确定了靶向第二个新的血液组织限制性激酶靶点的新机会:G蛋白偶联受体6(GRK 6)。因此,我们提出了一个雄心勃勃的短期和中期计划,以进一步临床开发和理解CDK 5抑制剂SCH 727965活性的分子基础,同时通过追求靶向GRK 6的新型化学实体来实现更长远的目标。该提案的目的是:1)通过在晚期骨髓瘤中进行SCH 727965与蛋白酶体抑制剂Carfilzelatin组合的Ib/II期临床试验,进一步推进临床中的CDK 5抑制疗法,2)作为该临床试验的一部分,我们将检查组合疗法的敏感性和抗性的体内介质,3)使用从120,我们将检查一组40种新型GRK 6特异性抑制剂的靶特异性、效力、体内活性和针对骨髓瘤的毒性。作为先导化合物优化和早期临床开发的前奏,将评估先导化合物的毒性特征,4)我们将继续分析BTZ致敏筛选中确定的靶点
还没有完全验证。我们早期关注GRK 6和CDK 5作为具有最高表观治疗指数的最强命中,但在我们的RNA干扰筛选中鉴定的其他新颖且有趣的蛋白酶体抑制剂敏化靶点需要进一步验证和分析,包括敏化剂BAZ 1B、CDC 42 SE 2、MDM 4、NME 7、RAB 8B、TFE 3、TNFAIP 3、TNK 1、TOP 1、VAMP 2和YY 1。因此,所提出的工作具有高度创新性,追求至少两个新的和新颖的靶点以获得临床结论,并且具有重要意义,因为需要骨髓瘤治疗的进一步突破和新的治疗靶点来将疾病从可控变为可治愈。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ALEXANDER KEITH STEWART其他文献
ALEXANDER KEITH STEWART的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ALEXANDER KEITH STEWART', 18)}}的其他基金
Project 1 - High Throughtput Drug Screening and Correlations with Mutational Status in Myeloma Cell Lines and Patient Samples
项目 1 - 高通量药物筛选及其与骨髓瘤细胞系和患者样本突变状态的相关性
- 批准号:
10006208 - 财政年份:2020
- 资助金额:
$ 43.19万 - 项目类别:
Project 3 - Modeling Proteasome Inhibitor Response and Resistance in Cell Lines and Patient Samples with Single Cell Analysis of Subpopulations
项目 3 - 通过亚群的单细胞分析来模拟细胞系和患者样本中的蛋白酶体抑制剂反应和耐药性
- 批准号:
9444854 - 财政年份:2017
- 资助金额:
$ 43.19万 - 项目类别:
Project 1 - High Throughtput Drug Screening and Correlations with Mutational Status in Myeloma Cell Lines and Patient Samples
项目 1 - 高通量药物筛选及其与骨髓瘤细胞系和患者样本突变状态的相关性
- 批准号:
9444852 - 财政年份:2017
- 资助金额:
$ 43.19万 - 项目类别:
Translation of Novel Therapeutic Targets in Multiple Myeloma
多发性骨髓瘤新治疗靶点的转化
- 批准号:
8442203 - 财政年份:2013
- 资助金额:
$ 43.19万 - 项目类别:
Translation of Novel Therapeutic Targets in Multiple Myeloma
多发性骨髓瘤新治疗靶点的转化
- 批准号:
8990732 - 财政年份:2013
- 资助金额:
$ 43.19万 - 项目类别:
Translation of Novel Therapeutic Targets in Multiple Myeloma
多发性骨髓瘤新治疗靶点的转化
- 批准号:
9191248 - 财政年份:2013
- 资助金额:
$ 43.19万 - 项目类别:
Translation of Novel Therapeutic Targets in Multiple Myeloma
多发性骨髓瘤新治疗靶点的转化
- 批准号:
8606833 - 财政年份:2013
- 资助金额:
$ 43.19万 - 项目类别:
相似国自然基金
bortezomib抑制寨卡病毒复制的分子机制研究
- 批准号:82272328
- 批准年份:2022
- 资助金额:52 万元
- 项目类别:面上项目
蛋白酶体抑制剂硼替佐米(Bortezomib)对血管渗漏的改善及机制研究
- 批准号:81772041
- 批准年份:2017
- 资助金额:55.0 万元
- 项目类别:面上项目
蛋白酶体抑制剂Bortezomib对肺动脉平滑肌细胞钙离子通路的作用研究
- 批准号:81460011
- 批准年份:2014
- 资助金额:40.0 万元
- 项目类别:地区科学基金项目
相似海外基金
Invovlvement of increased vascular permeability in bortezomib-induced lung toxicity
血管通透性增加参与硼替佐米诱导的肺毒性
- 批准号:
21K06703 - 财政年份:2021
- 资助金额:
$ 43.19万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Elucidation of the mechanisms of bortezomib resistance in multiple myeloma and strategies to overcome them
阐明多发性骨髓瘤硼替佐米耐药机制及克服策略
- 批准号:
20K15978 - 财政年份:2020
- 资助金额:
$ 43.19万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Investigation of the mechanism of Rho-mediated pulmonary vascular permeability enhancement using bortezomib.
使用硼替佐米研究 Rho 介导的肺血管通透性增强机制。
- 批准号:
19K17652 - 财政年份:2019
- 资助金额:
$ 43.19万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
A randomized phase II trial of bortezomib-based therapy plus doxycycline vs. bortezomib-based chemotherapy plus standard supportive therapy in cardiac AL amyloidosis
一项基于硼替佐米的治疗加多西环素与基于硼替佐米的化疗加标准支持治疗治疗心脏 AL 淀粉样变性的随机 II 期试验
- 批准号:
352865 - 财政年份:2016
- 资助金额:
$ 43.19万 - 项目类别:
Operating Grants
Comparing and Combining Bortezomib and Mycophenolate in SSc Pulmonary Fibrosis
比较和联合硼替佐米和霉酚酸酯治疗 SSc 肺纤维化
- 批准号:
8822628 - 财政年份:2015
- 资助金额:
$ 43.19万 - 项目类别:
Role of Autophagy in Bortezomib-induced HNSCC Apoptosis
自噬在硼替佐米诱导的 HNSCC 细胞凋亡中的作用
- 批准号:
8909536 - 财政年份:2015
- 资助金额:
$ 43.19万 - 项目类别:
Role of Autophagy in Bortezomib-induced HNSCC Apoptosis
自噬在硼替佐米诱导的 HNSCC 细胞凋亡中的作用
- 批准号:
9208125 - 财政年份:2015
- 资助金额:
$ 43.19万 - 项目类别:
Defining the effects of bortezomib on NK cell activation in cancer
确定硼替佐米对癌症 NK 细胞活化的影响
- 批准号:
8475316 - 财政年份:2013
- 资助金额:
$ 43.19万 - 项目类别:
Defining the effects of bortezomib on NK cell activation in cancer
确定硼替佐米对癌症 NK 细胞活化的影响
- 批准号:
9088384 - 财政年份:2013
- 资助金额:
$ 43.19万 - 项目类别: